Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Jan 20, 2025 4:50pm
71 Views
Post# 36412408

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TODAY’S NUMBERS

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TODAY’S NUMBERSCG has Baxter over the barrel because they desperately need the cash from the sale of Vantive and it would be a disaster for Baxter if CG decided to walk away from the deal.  Baxter has billions of dollars in Bonds maturing and the refinance interest rate will be at least triple the rate of what the maturing bonds had.  The CG walk away threat to get Baxter to lower their price is what I am referring to as thumbscrews. 

CG/Vantive is already 100% locked into the PMX distribution deal, with its sales quotas and marketing commitments.  CG has no leverage over Spectral, plus, PMX is the only high margin product that CG can turn to in order to improve their overall margins and valuation metrics.  Nevermind the fact that CG also needs the world wide rights to EAA in order to get Toray to select them as their worldwide distribution partner for PMX.  

So I'm not really understanding what leverage you think CG will impose on Spectral during negotiations for the NA rights to PMX and the worldwide rights to EAA.  Please explain you logic Simon.     
<< Previous
Bullboard Posts
Next >>